Welcome to our dedicated page for Fortrea Holdings news (Ticker: FTRE), a resource for investors and traders seeking the latest updates and insights on Fortrea Holdings stock.
Fortrea Holdings (FTRE) is a leading global contract research organization (CRO) providing comprehensive clinical trial management and development services across all phases. This page aggregates official announcements, financial updates, and strategic developments for investors and industry professionals tracking the company's progress in biopharmaceutical research.
Access timely updates on clinical trial milestones, regulatory submissions, and partnership agreements that demonstrate Fortrea's operational capabilities. Our curated news collection helps stakeholders monitor the company's execution across its core services: Phase I-IV trial management, clinical pharmacology expertise, and patient access solutions.
Key updates include earnings reports, leadership changes, technology implementations, and significant contract awards. All content is verified through primary sources to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page for centralized access to Fortrea's latest developments in clinical research innovation and global trial management. Check regularly for updates reflecting the company's position as a pure-play CRO serving biopharma clients worldwide.
Fortrea (Nasdaq: FTRE) has announced the launch of its AI Innovation Studio, aimed at revolutionizing clinical trial execution with advanced AI and ML technologies. The studio will enhance speed, quality, and patient safety by automating repetitive tasks and empowering human-centric trial processes. Key innovations include smartphone-enabled data collection, large language models, and advanced predictive analytics. These initiatives are expected to improve patient recruitment, protocol optimization, and overall trial efficiency, contributing to Fortrea's vision for the future of the CRO industry.
Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), announced that its Chief Financial Officer, Jill McConnell, will participate in a virtual fireside chat hosted by Elizabeth Anderson, senior managing director at Evercore ISI. The event is scheduled for Thursday, June 20, 2024, at 2:00 pm ET, and will last for 30 minutes. Registration is required for the live event, and a replay will be available on the Fortrea Investor Relations website after the event.
Fortrea (Nasdaq: FTRE) has finalized the divestiture of its Endpoint Clinical and Fortrea Patient Access businesses to Arsenal Capital Partners. The deal allows Fortrea to focus on its core mission as a clinical contract research organization (CRO) while using the proceeds to reduce its debt structure. Endpoint Clinical and Fortrea Patient Access, both leaders in their respective fields, will benefit from Arsenal's expertise and resources. Sam Osman, former head of Fortrea's Enabling Services, will lead the newly independent entities as CEO, with Ray Hill serving as chairman.
Fortrea (Nasdaq: FTRE), a prominent global contract research organization (CRO), announced that its Chairman and CEO, Tom Pike, along with CFO Jill McConnell, will present at the Jefferies Global Healthcare Conference on June 5, 2024, at 11:00 am ET.
The presentation will be webcast live and accessible via Fortrea's Investor Relations website. A replay will be available post-event.
Fortrea (Nasdaq: FTRE), a global contract research organization, announced the appointment of Machelle Sanders to its Board of Directors on May 16, 2024.
Ms. Sanders, who has been North Carolina's Secretary of Commerce since February 2021, brings over 30 years of experience in operational and quality assurance roles within the pharmaceutical and biotechnology sectors.
Tom Pike, Fortrea’s chairman and CEO, highlighted her life sciences background and leadership skills as valuable assets for advancing Fortrea's differentiation strategy and delivering life-changing treatments faster.
Ms. Sanders expressed her enthusiasm for joining the Board and acknowledged the critical role of CROs in bringing new treatments to market.
Fortrea (Nasdaq: FTRE) reported financial results for Q1 2024 with revenues of $662.1 million, a GAAP net loss of $81.6 million, and adjusted EBITDA of $29.5 million. The company plans to divest assets related to Endpoint Clinical and Patient Access businesses. The book-to-bill ratio was 1.11x, with a backlog of $7.4 billion. Fortrea aims to be a top choice for clinical research organizations and is focused on differentiation to drive growth.
Fortrea, a leading global contract research organization (CRO), has rescheduled the release of its first quarter 2024 financial results to May 13, 2024. This delay is due to ongoing accounting and discontinued operations matters following a recent asset divestiture agreement. The company will host a conference call on the release date to discuss the financial results and conduct a Q&A session.
FAQ
What is the current stock price of Fortrea Holdings (FTRE)?
What is the market cap of Fortrea Holdings (FTRE)?
